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Abstract
Purpose Despite remarkable clinical responses and prolonged survival across several cancers, not all patients benefit from PD-1/
PD-L1 immune checkpoint blockade. Accordingly, assessment of tumour PD-L1 expression by immunohistochemistry (IHC) is
increasingly applied to guide patient selection, therapeutic monitoring, and improve overall response rates. However, tissue-
based methods are invasive and prone to sampling error. We therefore developed a PET radiotracer to specifically detect PD-L1
expression in a non-invasive manner, which could be of diagnostic and predictive value.
Methods Anti-PD-L1 (clone 6E11, Genentech) was site-specifically conjugated with DIBO-DFO and radiolabelled with 89Zr
(89Zr-DFO-6E11). 89Zr-DFO-6E11 was optimized in vivo by longitudinal PET imaging and dose escalation with excess
unlabelled 6E11 in HCC827 tumour-bearing mice. Specificity of 89Zr-DFO-6E11 was evaluated in NSCLC xenografts and
syngeneic tumour models with different levels of PD-L1 expression. In vivo imaging data was supported by ex vivo
biodistribution, flow cytometry, and IHC. To evaluate the predictive value of 89Zr-DFO-6E11 PET imaging, CT26 tumour-
bearing mice were subjected to external radiation therapy (XRT) in combination with PD-L1 blockade.
Results 89Zr-DFO-6E11 was successfully labelled with a high radiochemical purity. The HCC827 tumours and lymphoid tissue
were identified by 89Zr-DFO-6E11 PET imaging, and co-injection with 6E11 increased the relative tumour uptake and decreased
the splenic uptake. 89Zr-DFO-6E11 detected the differences in PD-L1 expression among tumour models as evaluated by ex vivo
methods. 89Zr-DFO-6E11 quantified the increase in PD-L1 expression in tumours and spleens of irradiated mice. XRT and anti-
PD-L1 therapy effectively inhibited tumour growth in CT26 tumour-bearing mice (p < 0.01), and the maximum 89Zr-DFO-6E11
tumour-to-muscle ratio correlated with response to therapy (p = 0.0252).
Conclusion PET imaging with 89Zr-DFO-6E11 is an attractive approach for specific, non-invasive, whole-body visualization of
PD-L1 expression. PD-L1 expression can be modulated by radiotherapy regimens and 89Zr-DFO-6E11 PET is able to monitor
these changes and predict the response to therapy in an immunocompetent tumour model.
Keywords Molecular imaging . Positron emission tomography (PET) . PD-L1 . Immunotherapy . Immune checkpoint inhibition
Introduction
Immune checkpoint therapy has recently emerged as an effec-
tive way of evading the immunosuppressive tumour microen-
vironment thus allowing the immune system to eradicate tu-
mours. One of the major checkpoints probed for therapy is
programmed cell death protein 1 (PD-1), most prominently
expressed on the surface of T cells, B cells, and natural killer
cells, and its inducible ligand programmed death ligand 1
(PD-L1) naturally expressed on a variety of cell types includ-
ing some tumour cells, hepatocytes, muscle cells, epithelium
and antigen-presenting cells [1]. To date, PD-1/PD-L1 anti-
bodies have been approved for treatment of several cancers
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including melanoma, renal cell carcinoma, non-small cell lung
cancer (NSCLC) and bladder cancer—and the list is rapidly
expanding [2]. Durable, clinical responses and long-term sur-
vival across several tumour types have anchored the clinical
utility of immune checkpoint therapy. However, in many can-
cers, the response rates are not impressive with a large propor-
tion of non-responding patients.
Therefore, precise methods to reliably identify patients
most likely to benefit from immune checkpoint inhibitors are
needed as they have the potential to improve the overall re-
sponse rates. Existing companion diagnostics to select patients
eligible for anti-PD-L1 therapy include ex vivo assessment of
PD-L1 expression in tumours by immunohistochemistry
(IHC) [3, 4]. However, patient biopsies are randomly sampled
and often poorly reflect the intra-tumour heterogeneity, tem-
poral dynamics, and prospective metastasis. Moreover,
responding patients with PD-L1 negative tumours as well as
non-responding patients with PD-L1 positive tumours have
been reported during the course of anti-PD-L1 therapy [5,
6]. Adding to this, assessing responses to immunotherapy by
standard RECIST criteria may be challenging compared with
conventional chemotherapy as tumour cells are not killed di-
rectly and the fact that pseudo progression often is observed in
patients receiving immune checkpoint inhibitors [7–9].
Molecular imaging with positron emission tomography
(PET) has the potential to overcome some of these challenges
by allowing a more comprehensive look at the entire tumour
and tumour burden including metastases in vivo. Further, the
non-invasive and quantitative nature of PET combined with
high sensitivity allows for rapid assessment of unique bio-
markers of response potentially guiding therapy decisions.
Consequently, progress has been made in PET imaging of the
PD-1/PD-L1 axis. Full-length antibody-based PET tracers spe-
cific for human, mouse as well as humanized cross-reactive to
mouse PD-L1 have been developed [10–12]. In particular, the
clinical efficacy of atezolizumab in NSCLC, melanoma, blad-
der cancer, and renal cell carcinoma has gained attention and
concurrently prompted the development of atezolizumab-based
tracers preclinically as well as clinically [13–17].
While the majority of these studies have demonstrated spe-
cific PD-L1 imaging in syngeneic, xenograft, and humanized
mouse tumour models, only a few has investigated the predic-
tive value of pre-treatment immuno-PET imaging with
atezolizumab [17]. In the present study, we radiolabelled a
monoclonal antibody similar to atezolizumab (clone 6E11),
a humanized PD-L1 antibody cross-reactive to mouse PD-
L1, with zirconium-89 (89Zr). Given our experience with
site-specific labelling by glycan modification [18], 6E11 was
conjugated site-specifically and evaluated in NSCLC xeno-
grafts and syngeneic mouse tumour models with varying
PD-L1 expression. Lastly, the utility of 89Zr-DFO-6E11 as
an in vivo biomarker of response to anti-PD-L1 therapy was
evaluated in immunocompetent mice.
Materials and methods
Cell culture and animal models
Human NSCLC cancer cells H1703 (ATCC CRL- 5889),
H1993 (ATCC CRL-5909), HCC827 (ATCC, CRL-2868),
murine colon carcinoma cells CT26.WT (ATCC, CRL-
2638), and murine melanoma cells B16-F10 (ATCC, CRL-
6475) were cultured according to standard procedures. All cell
lines were obtained from LGC standards and tested negative
for mycoplasma and a panel of murine pathogens.
H1703, H1993, and HCC827 cells were harvested in their
exponential growth phase and resuspended at 1:1 in complete
growth media and Matrigel™ (BD Biosciences) at a concen-
tration of 50 × 106 cells/mL. A 100-uL cell suspension (5 ×
106 cells/tumour) was injected subcutaneously into the flanks
(1 tumour/mouse) above the hind limbs in 7-week-old female
NMRI nude mice (Janvier Labs). CT26.WT and B16-F10
cells were harvested in their exponential growth phase and
resuspended in PBS at a concentration of 0.3 × 106 cells/mL.
A 100-μL cell suspension (300,000 cells/tumour) was injected
subcutaneously into the flank (1 tumour/mouse) above the
hind limbs in 7-week-old female BALB/c (CT26.WT) or
C57BL/6 (B16-F10) mice (Janvier Labs).
Tumours used for longitudinal imaging and biodistribution
studies were grown until ~ 300 mm3 while tumours for the
efficacy study were grown until ~ 100–150 mm3 prior to
treatment.
Antibody conjugation, radiolabelling, and stability
measurements
Anti-PD-L1 (clone 6E11, Genentech) was site-specifically en-
zymatically modified on glycan chains or randomly conjugat-
ed to the desferrioxamine-p-benzyl-isothiocyanate (DFO-Bn-
NCS, Macrocyclics) chelator according to previously
established protocols [18]. GalT enzyme and UDP-GalNAz
substrate for the site-specific modification were obtained from
Thermo Fisher Scientific and endoglycosidase S2 was pur-
chased from Genovis. The radiochemical purity was deter-
mined by radio-thin layer chromatography (radio-TLC) using
an eluent of 50 mM EDTA (pH 5.5) on silica gel 60 TLC
plates, where the antibody construct remains at the baseline,
while 89Zr4+ ions and [89Zr]-EDTA elute with the solvent
front. The level of aggregates was estimated by size
exclusion-high-performance liquid chromatograph (SEC-
HPLC) on a Yarra™ 3 μm SEC-3000 Column 150 ×
7.8 mm (Phenomenex) with 0.1 M phosphate buffer pH 7 as
mobile phase.
The degree of labelling (DOL) of site-specifically labelled
89Zr-DFO-6E11 was determined by mass spectrometry and
the in vitro stability was evaluated up to 7 days after
radiolabelling in either PBS (4 °C) or mouse plasma (37 °C)
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at a concentration of 1.7 MBq/mL. Samples were withdrawn
up to 144 h after labelling. The radiochemical stability in
buffer and plasma was determined by radio-TLC and SEC-
HPLC as described above.
Immuno-reactivity and saturation binding assay
The immuno-reactivity of 89Zr-DFO-6E11 was assessed ac-
cording to the Lindmo assay [19]. Increasing concentrations
of HCC827 cells (3.91 × 105–5.0 × 107 cells/mL) were incu-
bated with 0.1-nM 89Zr-DFO-6E11 for 3 h at 4 °C. Cells were
centrifuged at 500g for 5 min and the supernatants and pellets
counted in a gamma counter (Wizard2, PerkinElmer). Cell-
bound radioactivity was calculated as the ratio of cell-bound
radioactivity to the total amount of added radioactivity.
The affinity of radiolabelled 6E11 was assessed by a satu-
ration binding assay. HCC827 cells were harvested, added in
triplicates (2 × 104 cells) to a MultiScreenHTS BV Filter Plate
1.2 μm (#MSBVN1250, Merck Millipore) and washed twice
in PBS. Eight different concentrations of 89Zr-DFO-6E11
(range 30 nM–0.01 nM) in PBS supplemented with 1% bo-
vine serum albumin (BSA) were added into the wells. A par-
allel series was prepared containing 100-fold excess
unlabelled 6E11 to assess non-specific binding. The plate
was incubated for 4 h at 4 °C. After incubation, the plate
was washed 3 times in PBS with 1% BSA using a vacuum
manifold (Macherey-Nagel, Fisher Scientific). The plastic
cover was removed from the plate bottom and the plate dried
in a heat cabinet. The dry filters were transferred to counting
tubes and counted in a gamma counter.
Flow cytometry of PD-L1 expression
The surface expression of PD-L1 was evaluated by flow cy-
tometry of H1703, H1993, HCC827, CT26, and B16F10 cell
cultures. Cells were harvested, washed in FACS buffer (PBS
without Ca2+ and Mg2+, 1% BSA, 0.5 mM EDTA, 0.1%
NaN3) and resuspended at 1 × 10
6 cells/mL. Human cell lines
(H1703, H1993, HCC827) were incubated with anti-human
PD-L1 antibody (#ab205921, Abcam) for 1 h at 4 °C, washed
and stained for 30 min at 4 °C with AF488-anti-human IgG
(#A11013, Life Technologies). Murine cell lines (CT26,
B16F10) were incubated with anti-murine PD-L1 antibody
(PE, #551892, BD) for 1 h at 4 °C. Cell-associated fluorescent
intensity was quantified using FACSCanto II (BD
Biosciences) and data analyzed using FlowJo Software
(v10.0.7, Tree Star Inc.).
Optimization of antibody dose
The optimal protein dose for PET imaging was investigated by
an ex vivo biodistribution study with randomly labelled 89Zr-
DFO-6E11. HCC827 tumour-bearing mice were randomized
into five groups (N = 3/group) and injected immediately after
end-of-synthesis (EOS) via the tail vein with 1.92 ± 0.02
(range 1.78–2.08) MBq 89Zr-DFO-6E11 diluted in 0.9% ster-
ile NaCl prior to injection (200 μL total volume). The protein
dose was 2.17 ± 0.03 (range 2.01–2.35) μg. Mice were co-
dosed with 0, 10, 30, 100, or 500 μg of unlabelled 6E11.
Blood was withdrawn by cardiac puncture and mice were
euthanized 144 h after injection. Tumours and organs were
resected, weighed, and the radioactivity counted in a gamma
counter.
Small animal PET/CT imaging
The optimal imaging time-point was assessed by longitudinal
small animal PET/CT imaging in HCC827 tumour-bearing
mice (N = 8). Mice were injected intravenously immediately
after EOS through the tail vein with 1.89 ± 0.02 (range 1.78–
2.01) MBq site-specifically labelled 89Zr-DFO-6E11 and
30 μg of unlabelled 6E11. Mice were anesthetized with
sevoflurane (4% in 65% N2, 35% O2) and subjected to PET/
CT imaging on an Inveon Multimodality PET/CT scanner
(Siemens) 4, 24, 72, and 144 h post-injection (300, 300,
600, and 1200 s PET acquisition time, respectively).
Following optimization of imaging time-point, specificity
of 89Zr-DFO-6E11 was evaluated in HCC827, H1993, and
H1703 xenograft mouse models (N = 7/model) as well as
CT26 and B16F10 syngeneic mouse models (N = 6/model).
Mice were injected intravenously immediately after EOS with
1.2 ± 0.09 (range 0.65–2.82) MBq. PET/CT imaging was con-
ducted 72 h post-injection (600 s PET acquisition time).
All images were reconstructed using a 3D maximum a
posteriori algorithm with CT-based attenuation correction.
Image analysis (Inveon Software, Siemens) was performed
by drawing CT-based region of interests (ROIs). The uptake
of 89Zr-DFO-6E11 was quantified as percent injected dose per
gram tissue (%ID/g) assuming a tissue density of 1 g/cm3.
Ex vivo biodistribution
A subgroup of mice (N = 3/model) was subjected to conven-
tional ex vivo biodistribution after the last imaging session.
Mice were euthanized, tumours and organs were resected,
weighed, and the radioactivity counted in a gamma counter.
Following counting, tumours were fixed in 4% paraformalde-
hyde for 24 h followed by transfer to 70% ethanol for paraffin
embedding.
Therapy
CT26 tumour-bearing mice were randomized into 4 treatment
arms: control, external radiation therapy (XRT), XRT + anti-
PD-L1, and anti-PD-L1 (N = 8/group). Mice from the XRT
and the XRT + anti-PD-L1 group were placed in the radiation
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chamber in a restrainer allowing total fixation of the leg and
the body was covered by lead shielding so that only the tu-
mour was exposed to radiation. Two gray (Gy) were dosed at a
rate of 1 Gy/min (320 kV, 12.5 mA) using a small animal
irradiator (XRAD-320, pXi, CT) for three consecutive days.
After the last radiation dose, mice from all groups were
injected with 1.12 ± 0.11 MBq 89Zr-DFO-6E11 + 30 μg
6E11 intravenously and subjected to PET/CT imaging 72 h
post-injection according to the above described protocol.
Maximum tumour uptakes were calculated as a mean of the
top 30% of hottest voxels. The tumour-to-muscle ratios were
calculated as tumour(mean)/muscle(mean) and tumour(max)/
muscle(mean). Following PET/CT imaging, subgroups of
mice (XRT + anti-PD-L1 and anti-PD-L1 group) received 6
doses of 10 mg/kg anti-mouse PD-L1 (10F.9G2, #BE0101,
BioXcell) every second or third day.
Immunohistochemistry
Formalin-fixed tumours were embedded in paraffin, sec-
tioned at 4 μm and mounted on SuperFrost ULTRA
PLUS slides (Thermo Fisher Scientific). Sections were
deparaffinized, rehydrated in a series of alcohols, and
microwaved in citrate buffer pH = 6 for heat-induced epi-
tope retrieval. Sections were blocked and stained with the
following antibodies: anti-human PD-L1 antibody
(#ab205921, Abcam) or anti-mouse PD-L1 (#ab238697,
Abcam). Primary antibodies were detected using the
EnVision + System-HRP labelled Polymer and Liquid
DAB + subs t r a t e ch romogen sy s t em (Ag i l en t
Technologies). All procedures were performed at room
temperature and all tumours were stained in the same
batch.
Statistical analyses
Data are stated as mean ± SEM. One-way ANOVA with
post hoc test corrected for multiple comparisons (Tukey)
was applied to test for tumour volumes between groups
(days 0 and 4), image contrast over the imaging time-
course, and the tumour uptake values across xenograft
and syngeneic models. Two-way ANOVA with repeated
measures and Tukey’s multiple comparisons test was
applied to compare tumour volumes over time.
Survival was analyzed using the Kaplan–Meier method
and the log-rank (Mantel–Cox test), where p < 0.008
was considered statistically significant when correcting
for multiple comparisons using the Bonferroni method.
P values ≤ 0.05 were considered statistically significant.
Statistical analyses were performed using GraphPad
Prism 8.0c (GraphPad Software).
Results
89Zr-DFO-6E11 synthesis, stability, and in vitro
characteristics
6E11 was successfully conjugated to DFO by site-specific
modification (Fig. 1a) and labelled with 89Zr with a radio-
chemical yield of 19.4 ± 3.8 MBq. Radiochemical purity
was > 99% as assessed by radio-TLC and aggregates were
estimated to < 5% by SEC-HPLC. A representative chromato-
gram of 89Zr-DFO-6E11 is shown in Fig. 1b. The specific
activity was 781.1 ± 140.5 MBq/mg and the DOL estimated
to 2. Tracer specifications are listed in Table 1, where data for
randomly conjugated 6E11 are included. 89Zr-DFO complex
of 89Zr-DFO-6E11 was stable in buffer (> 99% intact) after
144 h of incubation as determined by radio-TLC. Plasma sta-
bility of 89Zr-DFO-6E11 as determined by SEC-HPLC
showed 47% intact tracer after 144 h (Table S1).
The immuno-reactive fraction was estimated to 95% at
infinite antigen levels (Fig. 1c). 89Zr-DFO-6E11 exhibited af-
finity towards HCC827 (PD-L1 high expressing cells) in the
nanomolar range with an estimated KD of 0.23 nM (Fig. 1d).
Optimization of antibody dose
A titration study with increasing concentrations of co-injected
unlabelled 6E11 was performed in HCC827 tumour-bearing
mice to determine the optimal antibody dose for 89Zr-DFO-
6E11 imaging. The distribution of 89Zr-DFO-6E11 changed
considerably with increasing dose with primary differences ob-
served in terms of tumour, liver, and splenic uptake (Table 2).
The tumour uptake increased from 0.35 ± 0.04 %ID/g in
mice receiving no co-dose to 3.07 ± 0.15 %ID/g in mice re-
ceiving a 500-μg co-dose, while the spleen uptake decreased
from 14.44 ± 3.10 %ID/g in mice receiving no co-dose to
3.36 ± 0.09 %ID/g in mice receiving a 500-μg co-dose. The
decrease in splenic uptake was also confirmed by the spleen-
to-blood and spleen-to-muscle ratios (Table 3). The tumour-
to-blood ratio increased from 9.01 ± 1.82 to 41.94 ± 1.84 with
a 30-μg co-injection of unlabelled 6E11, while co-injection
with 100 and 500 μg decreased the ratio further below the
non-titrated dose uptake approximating blocking levels. To
be noted is the distribution of 89Zr-DFO-6E11 in the liver with
increasing dose. Liver uptake decreased from 7.99 ± 0.03 to
2.90 ± 0.11 with no and a 500-μg co-dose, respectively,
confirming this site as primary clearance route. Based on these
results, a co-injection of 30μg of unlabelled 6E11 was applied
in all further experimentation.
Longitudinal PET/CT imaging
The temporal in vivo distribution of 89Zr-DFO-6E11 was
assessed by longitudinal PET/CT imaging in HCC827
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tumour-bearing mice 4, 24, 72, and 144 h post-injection.
Representative PET/CT images from the same mouse at each
time point are illustrated in Fig. 2a and show targeting of 89Zr-
DFO-6E11 to the HCC827 tumours and lymphoid tissue. The
distribution in major organs is depicted in Fig. 2b and con-
firmed clearance of 89Zr-DFO-6E11 primarily through the
hepatobiliary system.
The average tumour uptake was 2.7 ± 0.20, 5.12 ± 0.43, 5.1
± 0.64, and 3.72 ± 0.11 %ID/g for the 4, 24, 72, and 144h time-
point, respectively (Fig. 2c). Likewise, the maximum uptake
within tumours was 7.9 ± 0.6, 12.8 ± 0.91, 11.9 ± 1.1, and
10.0 ± 0.28 %ID/g for the 4, 24, 72, and 144h time-point, re-
spectively. No further improvement in tumour-to-muscle ratio
was observed from 72 to 144 h (p = 0.9895) and 72 h post-
injection was thus chosen as optimal imaging time-point (Fig.
2d). Ex vivo biodistribution after the last imaging time-point
confirmed the PET data obtained in vivo with accumulation
primarily seen in the liver, spleen, and tumour (Fig. 2e).
Specificity of 89Zr-DFO-6E11
The ability of 89Zr-DFO-6E11 to image PD-L1 expression was
evaluated in three NSCLC xenografts (H1703, H1993, and
HC827) and two syngeneic models (CT26 and B16F10) with
different PD-L1 expression levels. Initially, the expression lev-
el of all models was evaluated by flow cytometry, and data
showed that H1703 could be characterized as low, H1993 as
intermediate, and HCC827, CT26, and B16F10 as high PD-L1
expressing cell lines, relative to each other (Fig. 3a). The PD-
L1 expression levels were further confirmed by IHC (Fig. 3b).
To evaluate the in vivo specificity of 89Zr-DFO-6E11, PET/
CT imaging was applied to the same panel of tumour models
and uptake quantified 72 h post-injection. 89Zr-DFO-6E11
detected the variation in PD-L1 expression as shown by the
representative PET/CT images (Fig. 3c) and the mean in vivo
tumour uptake across models thus confirming the cross-
reactivity of 6E11 (Fig. 3d). The mean tumour uptake was
1.35 ± 0.1, 2.32 ± 0.2, 5.1 ± 0.6, 8.26 ± 0.6, and 10.78 ± 0.9
%ID/g for the H1703, H1993, HCC827, CT26, and B16F10
model, respectively. The uptake in HCC827 tumours was sig-
nificantly different from the uptake in H1703 (p = 0.0003) and
H1993 (p = 0.0075). Also, the uptake in CT26 and B16F10
tumours was significantly different (p = 0.0414) and were
both significantly increased compared with H1703
Fig. 1 Tracer development and validation. a Graphical illustration of
6E11 chelator conjugation using endoglycosidase S2 and DIBO-DFO
yielding 2 chelates per antibody on the heavy chain glycans. b HPLC
chromatogram of 89Zr-DFO-6E11. c Immuno-reactivity assay of 89Zr-
DFO-6E11 incubated with HCC827 cells (high PD-L1 expression). d
Saturation binding assay of 89Zr-DFO-6E11 incubated with HCC827
cells. CPM, counts per minute; DIBO-DFO, dibenzocyclooctyne-
desferrioxamine; IRF, immuno-reactive fraction; KD, dissociation
constant
Table 1 Specifications of 89Zr-DFO-6E11
89Zr-DFO-6E11
Random Site-specific
Radiochemical yield (MBq) 23.5 ± 6.4 19.4 ± 3.8
Purity HPLC (%) > 95 > 95
Aggregates (%) < 5 < 5
Purity radio-TLC (%) > 99 > 99
Specific activity (MBq/mg) 896.0 ± 45.7 781.1 ± 140.5
Immuno-reactivity (%) 65 95
KD (nM) 2.7 0.23
Degree of labelling (DOL) – 2
Values are mean ± SEM
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(p < 0.0001). Overall, the uptake levels corresponded to the
expression level shown by flow cytometry and IHC.
Furthermore, gamma counting of tumours confirmed the up-
take levels of 89Zr-DFO-6E11 measured by PET (Fig. 3e).
Therapy-induced changes in PD-L1 expression
detected with 89Zr-DFO-6E11
Based on the numerous ongoing clinical efforts exploring the
possible synergistic effects of immunotherapy combined with
conventional cancer treatments, we designed an immunother-
apy combination study with XRT and anti-PD-L1 therapy
(Fig. 4a). Initially, we evaluated whether 89Zr-DFO-6E11 could
detect the temporal dynamics of XRT-induced PD-L1 upregu-
lation in a pilot studywith CT26 tumour-bearingmice (Fig. 4b).
Despite a fractionated radiation dose delivered directly to tu-
mour the mean 89Zr-DFO-6E11 uptake was increased in both
the tumour (p = 0.0076) and the spleen (p = 0.0100) of treated
mice. Immunohistochemical staining of the same tumours con-
firmed an upregulation of PD-L1 expression and/or increased
presence of PD-L1 positive cells (Fig. 4c).
For the immunotherapy combination study, mice were
subjected to XRT, 89Zr-DFO-6E11 PET/CT, and concur-
rently dosed with anti-PD-L1. The mean (Fig. 4d, p =
0.0025) and maximum (Fig. 4e, p = 0.0005) tumour-to-
muscle ratio of 89Zr-DFO-6E11 was increased in
irradiated mice compared with control mice. Tumour
growth was effectively inhibited in the anti-PD-L1
(p = 0.0476) and XRT + anti-PD-L1 (p = 0.0023) treated
group compared with the control group on day 26 (last
day of control group). No effect of XRT alone was
observed (Fig. 4f, p = 0.1072). Similarly, overall survival
was improved in the anti-PD-L1 (p = 0.0024) and XRT
+ anti-PD-L1 (p = 0.0023) treated mice compared with
control mice (Fig. 4g).
Increased tumour-to-muscle ratio of 89Zr-DFO-6E11
in responding mice
To investigate the overall association of 89Zr-DFO-6E11 tu-
mour uptake and immunotherapeutic response to anti-PD-L1
therapy, the percent tumour growth increase at multiple days
post-treatment initiation was calculated and plotted against the
mean and maximum tumour-to-muscle ratios of 89Zr-DFO-
6E11. The day prior to start of anti-PD-L1 therapy (day 4),
there was no difference in tumour volumes between treatment
groups (Fig. S1, p = 0.4731). Representative PET/CT images
illustrating ROIs of the muscle and the tumour of a mouse are
shown in Fig. S2. Percent tumour growth increase was calcu-
lated for day 15, 19, 22, and 26 and represents the time frame
from when effect of therapy was evident from the tumour
growth curves (day 15) and to the latest time-point sufficient
Table 2 Effect of titration of
antibody dose on 89Zr-DFO-6E11
uptake determined by ex vivo
biodistribution 144 h post-
injection in HCC827 tumour-
bearing mice (N = 3/dose)
+ 0 μg + 10 μg + 30 μg + 100 μg + 500 μg
Blood 0.04 ± 0.01 0.04 ± 0.01 0.04 ± 0.00 0.45 ± 0.29 1.86 ± 0.38
Bone 3.07 ± 0.08 3.15 ± 0.08 2.87 ± 0.24 2.74 ± 0.04 1.19 ± 0.52
Heart 1.01 ± 0.05 0.49 ± 0.05 0.50 ± 0.05 0.57 ± 0.07 0.83 ± 0.05
Intestine 0.45 ± 0.13 1.13 ± 0.18 0.90 ± 0.07 0.78 ± 0.11 0.57 ± 0.05
Kidney 2.11 ± 0.28 1.36 ± 0.04 1.34 ± 0.07 1.42 ± 0.07 1.37 ± 0.07
Liver 7.99 ± 0.03 3.54 ± 1.18 3.81 ± 0.37 3.51 ± 0.09 2.90 ± 0.11
Lungs 3.82 ± 0.59 1.39 ± 0.60 1.09 ± 0.11 1.20 ± 0.14 1.62 ± 0.02
Muscle 0.28 ± 0.04 0.16 ± 0.03 0.16 ± 0.01 0.21 ± 0.07 0.68 ± 0.47
Pancreas 0.35 ± 0.02 0.47 ± 0.05 0.44 ± 0.03 0.34 ± 0.06 0.46 ± 0.03
Spleen 14.44 ± 3.10 8.11 ± 2.41 5.59 ± 0.51 4.25 ± 0.35 3.36 ± 0.09
Stomach 0.26 ± 0.01 0.31 ± 0.02 0.38 ± 0.07 0.39 ± 0.02 0.39 ± 0.02
Tumour 0.35 ± 0.04 1.09 ± 0.39 1.72 ± 0.24 3.15 ± 0.55 3.07 ± 0.15
Values are mean ± SEM
Table 3 Target-to-background
ratios of 89Zr-DFO-6E11
determined by ex vivo
biodistribution 144 h post-
injection in HCC827 tumour-
bearing mice (N = 3/dose)
Tumour/blood Tumour/muscle Spleen/blood Spleen/muscle
+ 0 μg 9.01 ± 1.82 1.25 ± 0.05 345.11 ± 34.65 56.61 ± 13.87
+ 10 μg 25.43 ± 4.00 7.28 ± 2.40 244.01 ± 100.9 47.26 ± 5.68
+ 30 μg 41.94 ± 1.84 10.74 ± 1.49 140.62 ± 15.58 34.69 ± 3.09
+ 100 μg 14.05 ± 4.70 17.23 ± 3.09 21.65 ± 8.47 24.75 ± 5.25
+ 500 μg 1.80 ± 0.33 10.34 ± 3.50 1.98 ± 0.37 11.20 ± 3.76
Values are mean ± SEM
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numbers of mice were left in the control group (day 26). There
was no association between percent tumour growth increase
(day 26/4) and the mean tumour-to-muscle ratio in anti-PD-L1
treated mice (Fig. 4h, r2 = 0.2460, p = 0.0507). However, a
significant negative correlation between percent tumour
growth increase (day 26/4) and the maximum tumour-to-
muscle ratio in anti-PD-L1 treated mice was found (Fig. 4i,
r2 = 0.3097, p = 0.0252). Similarly, an association between
percent tumour growth increase (day 15/4) and the maximum
tumour-to-muscle ratio in anti-PD-L1 treated mice (Fig. S3b,
r2 = 0.2973, p = 0.0289) was found. The recorded tumour
growth on day 19 and 22 was not found to be associated with
the 89Zr-DFO-6E11 tumour-to-muscle ratio (Fig. S3c–f).
Discussion
Immunohistochemistry assays of tumour biopsies to
evaluate immune checkpoint target expression have
recently been implemented in the clinical routine to se-
lect patients eligible for immune checkpoint inhibition.
However, it is becoming increasingly clear that immune
checkpoint targets are highly dynamic and a better un-
derstanding of the spatiotemporal dynamics of the
tumour-immune microenvironment, which is difficult to
obtain with a single biopsy, is critical for effective ther-
apies to be developed and clinically applied [20].
In the present study, we evaluated the ability of 89Zr-DFO-
6E11 to visualize and quantify the therapy-induced changes in
PD-L1 expression following radiotherapy and the predictive
value of 89Zr-DFO-6E11 PD-L1 PET prior to immune check-
point blockade of PD-L1. Due to the high non-tumour (i.e.,
lymphoid tissue) expression of PD-L1, we initially sought to
define the optimal antibody dose by decreasing the uptake in
endogenous tissue—a common optimization approach in PET
imaging studies. Increasing the administered antibody dose to
30 μg decreased the splenic uptake from 14.44 ± 3.10 to 5.59
± 0.51 %ID/g and concurrently allowed visualisation of
Fig. 2 Small animal 89Zr-DFO-6E11 PET/CT in HCC827 tumour-
bearing mice. a Representative PET/CT images of the same mouse at 4,
24, 72, and 144 h post-injection of 89Zr-DFO-6E11 illustrating targeting
to lymphoid tissue and tumour. b Image-derived biodistribution over the
imaging time-course in major organs. c Average (mean) and maximum
(max) tumour uptake of 89Zr-DFO-6E11 expressed as %ID/g at 4, 24, 72,
and 144 h post-injection. d Tumour-to-heart and tumour-to-muscle ratios
of the mean 89Zr-DFO-6E11 uptake over the imaging time-course. e Ex
vivo biodistribution measured by gamma counting of 89Zr-DFO-6E11
after the last imaging session 144 h post-injection. N = 8 for all time
points except 144 h, where N = 3. Data are presented as mean ± SEM.
%ID/g = % injected dose per gram tissue. ALN, axillary lymph node;
CLN, cervical lymph node
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tumour PD-L1 by increasing the tumour uptake ~ 5-fold from
0.35 ± 0.04 to 1.72 ± 0.24 %ID/g. Additionally, the non-
specific liver uptake decreased with increasing dose
confirming this organ as the major site of clearance of 6E11.
PD-L1 is not a traditional tumour imaging target as the expres-
sion is higher in non-tumour tissues, and it can be argued that
it is not desired to block lymphoid uptake completely as 89Zr-
DFO-6E11 uptake in these tissues might serve as a surrogate
for activation state of the body’s immune system. In addition,
choosing a dose that saturates the antigen sink in lymphoid
tissue completely might tip the balance in another individual
and potentially block tumour target. Indeed, it has been sug-
gested that low specific activity 89Zr-DFO-6E11 may be need-
ed to accurately determine tumour PD-L1 expression levels
[21].
In vivo imaging confirmed a similar distribution pattern with
highest 89Zr-DFO-6E11 uptake in lymph nodes and spleen in
HCC827 tumour-bearing mice. Gamma counting of the spleen
after the last imaging time-point was higher than the uptake
measured by PET ROI analysis (~ 14 ex vivo vs. 6.5 in vivo
%ID/g) most likely due to limited image contrast and the partial
volume effect introduced by PET ROI quantification of the
Fig. 3 Specificity of 89Zr-DFO-6E11 in xenograft and syngeneic mouse
tumour models. a Flow cytometric analysis of various cell lines for
surface expression of PD-L1 using PE-conjugated anti-human or anti-
mouse PD-L1 antibody. Data are presented as a mean of three indepen-
dent experiments. b Ex vivo immunohistochemical staining of PD-L1 in
NSCLC and syngeneic tumour models. c Representative PET/CT images
of the H1703, H1993, HCC827 NSCLC xenografts, and CT26 and
B16F10 syngeneic tumour models 72 h post-injection of 89Zr-DFO-
6E11 illustrating targeting to lymphoid tissue and the tumour (indicated
by arrows). dMean tumour uptake of 89Zr-DFO-6E11 72 h post-injection
quantified by PET ROI analysis and expressed as %ID/g (N = 7 for xe-
nograft models,N = 6 for syngeneic models). e Ex vivo uptake in tumours
of 89Zr-DFO-6E11 72 h post-injection of the different models measured
by gamma counting (N = 3/model). Data are presented as mean ± SEM
and the significance levels are indicated by asterisks (*). *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001. %ID/g, percent injected dose per
gram tissue; MFI, median fluorescent intensity; PE-A, phycoerythrin-
area; NSCLC, non-small cell lung cancer
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spleen. The mean and maximum tumour uptake differed sub-
stantially, indicative of a relatively heterogeneous tumour
uptake of 89Zr-DFO-6E11. No further increase in tumour-to-
background ratios was observed beyond 72 h, which also has
Fig. 4 Treatment monitoring and prediction of anti-PD-L1 efficacy with
89Zr-DFO-6E11 in CT26 tumour-bearing immunocompetent mice. a
Overview of timing of model establishment, 89Zr-DFO-6E11 injections,
and therapy dosing (N = 8/group). Radiotherapy (XRT) was dosed 3
times (3 × 2 Gy) prior to 89Zr-DFO-6E11 injection and anti-mouse PD-
L1 antibody was dosed 6 times over 2 weeks (10 mg/kg). b Mean 89Zr-
DFO-6E11 uptake in tumours and spleens of control and XRT treated
(3 × 2 Gy) mice 72 h post-injection of 89Zr-DFO-6E11 (N = 6/group). c
Ex vivo immunohistochemical staining of PD-L1 in tumours of a control
and XRT treated mouse. d Mean tumour-to-muscle ratio of the 89Zr-
DFO-6E11 uptake in control and XRT treated mice (N = 16/group). e
Maximum tumour-to-muscle ratio of the 89Zr-DFO-6E11 uptake in con-
trol and XRT treated mice (N = 16/group). f Tumour volume over time
from the time of randomization (day 0) (N = 8/group). The gray area
represents the XRT treatment period and the blue area the anti-PD-L1
treatment period. g Overall survival of mice in the different treatment
groups (N = 8/group). h Tumour growth increase from day 4 to day 26
expressed as percent compared with the mean tumour-to-muscle (T/M)
ratio of 89Zr-DFO-6E11 (N = 16). i Tumour growth increase from day 4 to
day 26 expressed as percent compared with the maximum tumour-to-
muscle (T/M) ratio of 89Zr-DFO-6E11 (N = 16). All uptake values are
derived from PET ROI analysis and expressed as %ID/g. Data are pre-
sented as mean ± SEM and the significance levels are indicated by aster-
isks (*). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. %ID/g,
percent injected dose per gram tissue; XRT, external radiation therapy
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been confirmed as optimal imaging time-point for other
atezolizumab-based tracers [14, 15]. Overall, the tumour uptake
144 h post-injection found in the longitudinal imaging study
(Fig. 2) was approximately 2-fold higher than observed for the
dose escalation study (Table 2) with a 30-μg co-dose. This
discrepancy can be explained by the shift in antibody conjuga-
tion strategy to site-specifically labelled 89Zr-DFO-6E11. As
evident fromTable 1, site-specific 89Zr-DFO-6E11was present-
ed with higher immuno-reactivity, affinity, and stability—
factors known to influence target binding and accumulation.
Our in vivo PET imaging and biodistribution studies in five
different mouse models of humane and murine cancer clearly
demonstrated the PD-L1 binding specificity of 89Zr-DFO-
6E11, where the 89Zr-DFO-6E11 tumour uptake was consis-
tent with both in vitro and ex vivo findings. In general, the
models applied in this study were considered to be well suited.
Firstly, the cell lines used express endogenous levels of PD-L1
and are not engineered to express high, constitutive levels of
PD-L1 as the frequently used hCHO-PD-L1 cell line.
Secondly, due to the cross-reactivity of 89Zr-DFO-6E11, back-
ground levels are present, making it easier to compare preclin-
ical and clinical data. In the present study, the splenic PET
uptake did not differ between NMRI nude (8.2 ± 1.0 %ID/g,
Fig. 2b) and BALB/C mice (8.46 ± 0.48 %ID/g, data not
shown) 72 h post-injection. Thus, the background levels can
be considered comparable, and the 89Zr-DFO-6E11 tumour up-
take was compared across mouse strains. Evident from the flow
cytometric and IHC analysis of H1703, this cell line can be
considered PD-L1 negative, and the non-specific ~ 1.5 %ID/g
tumour uptake attributed to the enhanced permeability and re-
tention effect. The specificity for tumour PD-L1 was also con-
firmed by the dose escalation study, where a blocking tendency
was observed with increasing 6E11 co-dose. Even though tu-
mour uptake appeared high in HCC827 tumour-bearing mice
co-injected with 500 μg, this was expected as the endogenous
PD-L1 levels are blocked allowing for more tracer in the circu-
lation available for tumour accumulation. The tumour-to-
background ratios, however, witnessed that the tumour-to-
muscle and tumour-to-blood ratio decreased from 17.23 ±
3.09 to 10.34 ± 3.50 and 14.05 ± 4.70 to 1.80 ± 0.33, from a
100- to a 500-μg co-dose, respectively.
External radiation therapy is well known to upregulate tu-
mour PD-L1 expression levels, partially as a part of an immu-
nogenic anti-tumour immune response, and also as a resistance
mechanism to facilitate immuno-suppression and tumour relapse
[22–25]. For that reason, there is an increasing interest in com-
bining radiotherapy and immune checkpoint blockade to syner-
gistically improve therapeutic efficacy. We observed an in-
creased 89Zr-DFO-6E11 uptake in the spleens and tumours of
irradiated CT26 tumour-bearing mice, possibly originating from
a combination of increased expression levels and increased in-
filtration of PD-L1 positive cells due to the inflammatory state.
Noteworthy is that 89Zr-DFO-6E11 accurately detected the
peripheral changes in PD-L1 levels induced by local radiothera-
py with increased splenic uptake. This finding further highlights
the potential of PET-basedmethods for in vivo biomarker assess-
ment on a whole-body, non-invasive level and the clinical utility
of 89Zr-DFO-6E11 as an indicator of immune system activity.
The utility of antibody-based PD-L1 PET in irradiated
NSCLC tumours has also been investigated by Ehlerding
et al. [15], who also demonstrated a significant increase in
tumour uptake of 89Zr-DFO-atezolizumab after radiotherapy.
The uptake levels cannot be directly compared due to different
models, injected doses, and therapy regimen, but the signifi-
cant ~ 1.5-fold increase in tumour-to-muscle ratios of irradiat-
ed mice 72 h post-injection is equal to that obtained in this
study (20.68/14.09, 1.48-fold increase). Furthermore,
Ehlerding and colleagues showed that the source of PD-L1
originated from CD45+ as well as CD45− negative cells in
the NSCLC tumours. The expression of target on antigen-
presenting cells highlights the need for a biologically inert
imaging agent giving rise to concerns regarding the use of a
full-length antibody tracer for visualizing target expression.
However, the Fc engineering of atezolizumab aids in silencing
the effector functions merely leading to neutralization of re-
ceptors [26], thus supporting the usage of atezolizumab-based
tracers. Together, with the different read-outs from available
clinical companion diagnostic assays for anti-PD-L1 therapy
in mind [27, 28], this encourages the practice of imaging with
a radiolabelled version of the therapeutic antibody enabling
quantification of exact distribution pattern within the body and
the delivery to tumour prior to and during therapy.
Major questions arise in the search for a predictive biomarker
of response to immune checkpoint therapy. Indeed, it can be
questioned whether tumour PD-L1 is the most predictive bio-
marker since clinical responses have been reported among ~
15% of patients with PD-L1 negative tumours shown by IHC
[29]. Is the “failure” rate of prediction with the approved diag-
nostic assays due to limited sampling or to the unanswered facets
of PD-L1 biology, and in the latter case, is it then too simple
merely showing PD-L1 biology? Regardless of the cause, our
data indicate that 89Zr-DFO-6E11 can be used as a companion
diagnostic method to select patients eligible for PD-L1 blockade,
which recently have been backed up by clinical data [17]. We
found the maximum tumour-to-muscle ratios of 89Zr-DFO-6E11
CT26 tumour-bearing mice to correlate with response to anti-
PD-L1 therapy alone or in combination with radiotherapy. No
association with the mean tumour-to-muscle ratio was found.
This is agreeing well with the fact that maximum values of
tumour imaging markers are considered more robust indicators
of prognosis and are therefore the most commonly utilized mea-
sure in the clinic [30–32]. Together with the prominent expres-
sion of PD-L1 on antigen-presenting cells and the heterogenous
distribution, e.g., migration and clustering, of these within a tu-
mour, this could explain the superiority of themaximum tumour-
to-muscle ratio of 89Zr-DFO-6E11 for response prediction. To
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our knowledge, this is the first study correlating response to
immunotherapy with pre-therapy PD-L1 PET imaging in a pre-
clinical mouse model demonstrating its clinical potential.
Furthermore, we utilize a site-specific conjugation methodology
resulting in uniform, well-defined conjugates with minimal loss
of immuno-reactivity and high reproducibility. Together, this
highlights the enthusiasm for further clinical translation of site-
specific 89Zr-DFO-6E11. However, the results obtained herein
may not be generally applicable to all cancer types, models, and
treatments. Also, to determine an objective and reproducible
method, i.e., cutoff for PET tumour uptake or tumour-to-
muscle ratio, is critical for accurate stratification of patients in
future clinical studies. Future preclinical studies investigating
multiple tumour types, dosing regimens, and scan protocols will
elucidate whether 89Zr-DFO-6E11 is a true predictor of response
to PD-L1 immune checkpoint blockade.
Conclusion
Cancer therapeutics is progressively moving away from com-
pounds that target tumours broadly. Modulating immune re-
sponses by blockade of immune checkpoints, and indeed, the
dynamic nature of these, is beginning to be realized. We herein
show that 89Zr-DFO-6E11 PET specifically detects various de-
grees of PD-L1 expression levels at baseline and after radiother-
apy in mouse models of murine and human cancer. Importantly,
we demonstrated that the tumour-to-muscle ratio of 89Zr-DFO-
6E11 PET in this experimental setup was predictive of response
to PD-L1 immune checkpoint inhibition in a syngeneic mouse
tumour model. Moreover, 89Zr-DFO-6E11 PET might serve as
an early identifier of immune response activation in a clinical
setting, warranting the further clinical development to aid in
determining proper therapies and monitoring patient responses.
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